Troubled Immunocore Reawakens With New $130m Funding

Company Diversifies Into Hepatitis B

 
• By Andrew McConaghie
  
OXFORD, ENGLAND - JANUARY 25: A view on the streets in Oxford, England on 25 January, 2018
The Oxford, UK-headquartered company needs to generate proof of concept data for its T-cell receptor immunotherapy
Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

SpotifyApple PodcastsWebsite

More from Business

More from Scrip